Laidlaw & Company Suit Gets a Restraining Order over Dissemination of Misleading Information

Dan Solin, the New York best-selling author of the Smartest series of books states that “the ratio of bad investments advice to sound advice is 10:1.” For those working with the financial media, giving misleading information puts money in their pockets, but when it comes to the security sectors, there is a lot to consider than just earning a living.

Bad Investment Advice Knows No Boundaries
The reason being, the welfare of the investors, is at stake. A Canadian newspaper, The Globe and Mail published an article August 6, 2016, featuring Paul Harris on the “three top stock picks.” The partner and portfolio manager at Avenue Investment Management gives convincing explanations for his stockpiles that would woo some investors to the trading stocks. What the traders do not include in the data is the information on the predictive record of accomplishment.

Laidlaw & Company is an investment banking and brokerage firm that gives personalized advice on banking and wealth management to individuals and institutions in the United States and the United Kingdom. Laidlaw’s investment banking services include raising capital through equity placement with high net worth investors, arranging the national exchange listings AIM-listed transactions on the UK market, trading markets in US as well as initial public offerings. Wealth management services include financial planning, advisory on investment and managing portfolios. Additionally, on the investment banking services, Laidlaw offer stock repurchases, balance sheets optimization, and strategic alliances.

Mr. Matthew D. Eitner ss the CEO and Mr. James P. Ahern the managing partner and Head of Capital Markets at Laidlaw On December 10, 2015, Laidlaw, Matthew Eitner and Ahern received restraining orders from the US District Court for the District of Nevada. Relmada filed a lawsuit against the two for disseminating false and misleading proxy materials; Laidlaw made attempts to take control over Relmada Therapeutics Inc. Laidlaw & Company has its headquarters in New York.

Leave a Reply

Your email address will not be published. Required fields are marked *